Prognostic value of tumor budding in muscle-invasive urothelial carcinoma of the bladder.

IF 2.2 Q3 ONCOLOGY
Ahlem Bdioui, Asma Mahmoudi, Zaineb Lajmi, Maroua Krifa, Syrine Moussa, Oussema Belkacem, Mariem Alaya, Sarra Mestiri, Sihem Hmissa, Nabiha Missaoui
{"title":"Prognostic value of tumor budding in muscle-invasive urothelial carcinoma of the bladder.","authors":"Ahlem Bdioui, Asma Mahmoudi, Zaineb Lajmi, Maroua Krifa, Syrine Moussa, Oussema Belkacem, Mariem Alaya, Sarra Mestiri, Sihem Hmissa, Nabiha Missaoui","doi":"10.1186/s43046-025-00332-9","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUND: Bladder cancer is a common malignancy of the urogenital tract worldwide. Almost 20–30% of new cases are muscle-invasive, a complex pathology with significant clinical and biological variability. Despite treatment advances, predicting disease progression remains challenging due to the limitations of traditional prognostic factors. Identifying new markers, such as tumor budding (TB), could offer a promising breakthrough. The aim of this study was to evaluate TB in muscle-invasive urothelial carcinoma (UC) of the bladder and assess its clinicopathological and prognostic significance. METHODS: We conducted a cross-sectional analytical study of 84 cases of muscle-invasive UC of the bladder. TB was assessed based on the 2016 International Tumor Budding Consensus Conference guidelines and correlated with clinicopathological features and patient survival. RESULTS: The study included 77 men and 7 women, with a mean age of 68.13 ± 9.41 years. Histologically, ulcerative proliferative and infiltrative features were most common (58%), and high-grade tumors accounted for 92.9% of cases. Tumors were mainly classified as pT4a (40.5%), with lymph node metastasis observed in 34.3%. The mean overall survival was 23.07 ± 1.9 months. TB was present in 41.7% of cases, with Bd1 in 9.5%, Bd2 in 16.7%, and Bd3 in 15.5% of UCs. Significant correlations were found between TB and the pattern of the invasive front (p = 0.002), presence of carcinoma in situ component (p = 0.024), vascular emboli (p = 0.020), lymphatic emboli (p = 0.044), perineural invasion (p = 0.012), and parietal wall infiltration (p = 0.006). CONCLUSION: These findings suggest that TB serves as an independent histoprognostic predictor of the aggressiveness of muscle-invasive UC, warranting its inclusion in pathology reports and treatment protocols. However, to further validate these findings, large-scale prospective studies with standardized methods for evaluating TB are required. </p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"76"},"PeriodicalIF":2.2000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13313447/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-025-00332-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND: Bladder cancer is a common malignancy of the urogenital tract worldwide. Almost 20–30% of new cases are muscle-invasive, a complex pathology with significant clinical and biological variability. Despite treatment advances, predicting disease progression remains challenging due to the limitations of traditional prognostic factors. Identifying new markers, such as tumor budding (TB), could offer a promising breakthrough. The aim of this study was to evaluate TB in muscle-invasive urothelial carcinoma (UC) of the bladder and assess its clinicopathological and prognostic significance. METHODS: We conducted a cross-sectional analytical study of 84 cases of muscle-invasive UC of the bladder. TB was assessed based on the 2016 International Tumor Budding Consensus Conference guidelines and correlated with clinicopathological features and patient survival. RESULTS: The study included 77 men and 7 women, with a mean age of 68.13 ± 9.41 years. Histologically, ulcerative proliferative and infiltrative features were most common (58%), and high-grade tumors accounted for 92.9% of cases. Tumors were mainly classified as pT4a (40.5%), with lymph node metastasis observed in 34.3%. The mean overall survival was 23.07 ± 1.9 months. TB was present in 41.7% of cases, with Bd1 in 9.5%, Bd2 in 16.7%, and Bd3 in 15.5% of UCs. Significant correlations were found between TB and the pattern of the invasive front (p = 0.002), presence of carcinoma in situ component (p = 0.024), vascular emboli (p = 0.020), lymphatic emboli (p = 0.044), perineural invasion (p = 0.012), and parietal wall infiltration (p = 0.006). CONCLUSION: These findings suggest that TB serves as an independent histoprognostic predictor of the aggressiveness of muscle-invasive UC, warranting its inclusion in pathology reports and treatment protocols. However, to further validate these findings, large-scale prospective studies with standardized methods for evaluating TB are required.

膀胱肌肉侵袭性尿路上皮癌肿瘤出芽的预后价值。
背景:膀胱癌是世界范围内泌尿生殖道常见的恶性肿瘤。几乎20-30%的新病例是肌肉侵袭性的,这是一种复杂的病理,具有显著的临床和生物学变异性。尽管治疗取得了进步,但由于传统预后因素的局限性,预测疾病进展仍然具有挑战性。发现新的标记物,如肿瘤出芽(TB),可能会带来有希望的突破。本研究的目的是评估膀胱肌肉侵袭性尿路上皮癌(UC)的结核,并评估其临床病理和预后意义。方法:我们对84例膀胱肌肉侵袭性UC进行了横断面分析研究。结核病的评估基于2016年国际肿瘤萌芽共识会议指南,并与临床病理特征和患者生存相关。结果:男性77例,女性7例,平均年龄68.13±9.41岁。组织学上以溃疡性增生性和浸润性特征最为常见(58%),高级别肿瘤占92.9%。肿瘤以pT4a类型为主(40.5%),伴有淋巴结转移(34.3%)。平均总生存期为23.07±1.9个月。41.7%的病例存在结核病,其中Bd1占9.5%,Bd2占16.7%,Bd3占15.5%。结核与侵袭前形态(p = 0.002)、原位癌成分(p = 0.024)、血管栓塞(p = 0.020)、淋巴栓塞(p = 0.044)、神经周围浸润(p = 0.012)、壁壁浸润(p = 0.006)有显著相关性。结论:这些发现表明,结核病是肌肉侵袭性UC侵袭性的独立组织预后预测因子,有必要将其纳入病理报告和治疗方案。然而,为了进一步验证这些发现,需要采用标准化的结核病评估方法进行大规模前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
46
审稿时长
11 weeks
期刊介绍: As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书